Ascentage Pharma Group International Unveils New Clinical Data at ASH 2025
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced that several of its investigational programs will be presented at the 67th American Society of Hematology (ASH) Annual Meeting in Chicago. The company’s latest results, spanning multiple studies of its flagship drug olverembatinib (HQP1351) and its BCL‑2 inhibitor lisaftoclax, underscore its continued focus on advanced oncology therapies.
Olverembatinib Continues to Garner Attention
Olverembatinib, a third‑generation BCR‑ABL inhibitor, has been the centerpiece of Ascentage Pharma’s oncology portfolio. In 2025, the company revealed that data from the POLARIS‑1 study—a pivotal trial evaluating olverembatinib in patients with Philadelphia chromosome‑positive acute lymphoblastic leukemia—will be showcased at ASH. This marks the eighth consecutive year that Ascentage’s olverembatinib data has been selected for presentation at the society’s flagship conference.
The inclusion of POLARIS‑1 data reflects the drug’s ongoing clinical momentum. As a first‑in‑class therapy approved in China, olverembatinib offers a differentiated mechanism of action that may benefit patients with T315I mutations and other resistance profiles that limit the efficacy of earlier‑generation TKIs.
Lisaftoclax Advances into Late‑Stage Development
Parallel to olverembatinib, Ascentage Pharma is progressing lisaftoclax, a novel BCL‑2 inhibitor designed to enhance apoptosis in cancer cells. Two separate clinical studies—one evaluating the oral formulation and another assessing combination strategies—will also be presented at ASH. The oral report, in particular, highlights the drug’s potential to improve patient convenience and adherence, a key consideration in chronic disease management.
APG‑5918 Adds to the Pipeline
In addition to olverembatinib and lisaftoclax, Ascentage Pharma will discuss preliminary data on APG‑5918, an investigational agent targeting a distinct molecular pathway. The company’s strategy of running concurrent studies across multiple therapeutic areas demonstrates its intent to diversify risk while maintaining a focused pipeline of high‑impact candidates.
Market Context and Company Position
As of 30 October 2025, Ascentage Pharma’s share price traded at HK$ 66.50, reflecting a market cap of approximately HK$ 24.5 billion. The company’s price‑earnings ratio of –17.59 signals that investors remain cautious, a common feature for clinical‑stage biotechs still awaiting commercial revenue. Nevertheless, the repeated selection of its data by ASH signals a robust scientific foundation and a credible reputation within the hematology community.
Strategic Implications
The ASH presentations provide Ascentage Pharma with a platform to engage with clinicians, payers, and regulatory authorities. Positive reception of the new data could accelerate regulatory submissions in key markets, including the United States and China. Moreover, the company’s dual listing on the Hong Kong Stock Exchange and its presence on NASDAQ enhance its visibility to a broad investor base, potentially supporting future capital-raising efforts.
As the company moves forward, stakeholders will monitor how the POLARIS‑1 and lisaftoclax studies translate into clinical outcomes, regulatory milestones, and ultimately, market access. The convergence of innovative science and strategic presentation at ASH 2025 positions Ascentage Pharma as a noteworthy player in the evolving landscape of targeted oncology therapies.
